Masimo Corp

Insider buying spikes as Masimo gears up for Danaher merger—insiders back the deal, boosting confidence in sensor tech and potential investor gains.

Masimo CFO’s 26‑Feb 2026 PSU exercise shows stable insider liquidity, while FDA/EMA approvals and robust trial data confirm the company’s leadership in non‑invasive patient monitoring.

Masimo insider trading signals confidence in its non‑invasive tech, showing a strategic bet on value‑based care, RPM growth, and a potential upside despite legal hiccups.